A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)

NCT05284032 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Platelet Refractoriness
Hematologic Malignancy

Interventions

DRUG: isatuximab 10 mg/kg

Sponsor

Firas El Chaer, MD